These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 24675266)
21. Regorafenib in the treatment of metastatic colorectal cancer. de la Fouchardière C Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472 [TBL] [Abstract][Full Text] [Related]
22. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Carter NJ Drugs Aging; 2014 Jan; 31(1):67-78. PubMed ID: 24276917 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908 [TBL] [Abstract][Full Text] [Related]
25. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748 [TBL] [Abstract][Full Text] [Related]
26. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Grothey A Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814 [No Abstract] [Full Text] [Related]
27. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766 [TBL] [Abstract][Full Text] [Related]
28. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Rutkowski P; Stępniak J Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387 [TBL] [Abstract][Full Text] [Related]
29. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491 [No Abstract] [Full Text] [Related]
30. [Regorafenib approved in Metastatic Colorectal cancer]. André T; Dumont SN Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557 [TBL] [Abstract][Full Text] [Related]
31. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185 [TBL] [Abstract][Full Text] [Related]
32. [Regorafenib in patients with metastatic colorectal cancer: a review and an update]. Zaniboni A; Mansueto G Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072 [TBL] [Abstract][Full Text] [Related]
33. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186 [TBL] [Abstract][Full Text] [Related]
34. Regorafenib in metastatic colorectal cancer. Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322 [TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer. Xue WS; Men SY; Liu W; Liu RH Medicine (Baltimore); 2018 Oct; 97(40):e12635. PubMed ID: 30290640 [TBL] [Abstract][Full Text] [Related]